Name | UC2288 |
Description | UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein stability. |
In vitro | UC2288 (0-10 μM; 24 hours) reduces p21 mRNA expression through transcriptional or post-transcriptional mechanisms, independent of p53, with no inhibition of VEGFR2 and Raf kinases, even at 10 μM[1]. |
In vivo | UC2288 (10 mg/kg; i.p.) attenuates MPTP-induced behavioral impairment, prevents activation of MAPK pathway in the MPTP-treated mice brain. MPTP treatment raises TNF-α, IL-6 and IL-1β levels in MPTP treated mice brain, but UC2288 signicantly decreases MPTP-induced TNF-α, IL-6 levels, but IL-1β is not decreased in brain[2].UC2888 (15 mg/kg; oral) co-treatment with imetelstat significantly suppresses tumor growth and does not effect mice weight[3]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 48 mg/mL (99.62 mM), Sonication is recommended.
|
Keywords | Attenuator | 786-O | Inhibitor | MDM-2/p53 | UC 2288 | inhibit | ovarian | UC2288 | RCC | HK2 | p21 | sorafenib | UC-2288 | p53-mutant | cancer |
Inhibitors Related | Milademetan | Alrizomadlin | Rotenone | XI-006 | RG7112 | DPBQ | BAY 1892005 | Indole-3-carbinol | Idasanutlin | Navtemadlin | RITA | P53R3 |
Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Anti-Cancer Metabolism Compound Library | Orally Active Compound Library | PPI Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Transcription Factor-Targeted Compound Library |